All the Drug Class Drugs
Tyrosine Kinase Inhibitor, VEGF Inhibitor. Axitinib 1 mg, 5 mg. FC. TAB 60 X 1/5 mg
Recomm. starting dose is 5 mg twice/d. Administer doses approx. 12 hs apart. Dose incr. or reduct. is based on indiv. safety and tolerab. See full prescript. data
Tmt. of adv.renal cell carcinoma (RCC) after failure of one prior syst. ther.
C/I: Hypersens.
Tyrosine Kinase Inhibitor. Dasatinib 20, 50, 70, 100 mg. FC Tabs: 60X 20, 50, 70mg,30X 100 mg. Recomm. starting dose for chron. phase CML is 100 mg dasatinib/d. Recomm. starting dose for accel., myeloid or lymphoid blast phase (adv. phase) CML or Ph+ ALL is 140 mg/d. Tmt. until dis. progress. or until no longer toler. by ptt. Dose incr. or reduct. based on ptt. resp. and tolerab.
Tmt. of adlt pts. with:
• Newly diagn. Philadelphia chrom. positive(Ph+ )
chronic myelogen. leukaemia (CML) in the chron. phase.
• Chronic, acceler. or blast phase CML with
resist. or intoler. to prior ther. incl. imatinib mesilate.
• Ph+ ac. lymphoblastic leukaemia(ALL) and lymphoid blast CML with resist. or intoler. to prior ther.
C/I:Hypersens.
Tyrosine Kinase Inhibitor. Erlotinib 25 mg, 100 mg, 150 mg. FC Tab 100,150 mg
Non-Small Cell Lung Cancer: daily dose of Erlotinib is 150 mg taken at least
one hour bef. or two hours after food.
Pancreatic cancer: daily dose of Erlotinib is 100 mg taken at least one hour bef. or two hours after food, in combin. with gemcitabine.
NSCLC (non-small cell lung cancer):
* First line tmt in pts with locally adv. or metast. NSCLC if cancer cells express mutations in EGFR.
* Maint. tmt. in pts with locally adv. or metast. NSCLC if cancer cells express mutations in EGFR and the dis. remains largely unchanged after initial chemother. trmt.
* Tmt of pts with locally adv. or metast. NSCLC if at least one prev. chemother. tmt. was unsuccessful in stopping the dis.
Pancreatic cancer:
* First line tmt in pts with locally adv., unresectable or metast. pancreatic cancer, in combin. with gemcitabine.
C/I: Hypersens.
Tyrosine Kinase Inhibitor. Erlotinib 100 mg, 150 mg. TABS: 30 x 100 mg, 150 mg. Non-small
cell lung cancer: 150 mg 1 x dly
without food. Pancreat. cancer: 100 mg
dly without food in comb. with
gemcitabine.
First-line tmt. locally advanced/metastat.
non-small cell lung cancer (NSCLC) with
EGFR activat. mutats. Tmt. locally.
advanced/metastat. NSCLC aft. fail. of at
least one prior chemother. reg. Monother.
for maint. tmt. pts with locally advanc./
metastat. non-small cell lung cancer
whose disease not progress. aft. 4 cycles of
platinum-based first-line chemother. In
comb. with gemcitabine for first-line tmt.
with locally advanced, unresect./
metastat. pancreat. cancer.
C/I: Hypersens.
Tyrosine Kinase Inhibitor. Imatinib 100 mg, 400 mg. F.C. TABS: 20, 60 x 100 mg; 10, 30 x
400mg.
Doses of 400 mg or 600 mg should be
admin. once dly., whereas a daily dose
of 800 mg should be admin. as 400 mg
×2/d in the morn. and even.
Tmt. of adult pts. and child. 3 yrs. of age
and above with Ph+ chron. myeloid
leukaemia (Ph+ -CML) in chron. phase
accelerat. phase or blast crisis. Glivec is
also indicat. for the tmt. of adult pts.s
with Kit (CD117) posit. unresect. and/or
metastat. malignant GI strom. tumour.
(GIST). Also indicated for the tmt. of :
Adult pts. with newly diagnosed
Philadelphia chromos. posit. acute
lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy. Adult pts.
with relapsed or refract. Ph + ALL as
monother. Adult pts. with unresect.
dermatofibrosarcoma protuberans
(DFSP) and adult pts. with recurrent and/
or metastat. DFSP who are not eligible
for surg. Adult pts. with myelodyspiastic/
myeloproliferative dis.(MDS/MPD) assoc.
with PDGFR ( platelet - derived growth
factor recept. ) gene re- arrangements.
Adult pts. with hypereosinophilic syndr.
(HES) and/or chronic eosinophilic
leukaemia (CEL) who have the FIP1L1-
PDGFRalfa fusion kinase (mutational
analysis or FISH demonstration fo CHIC2
allele deletion) and for pts. with HES and/
or CEL who are FIP1L1-PDGFR alfa fusion
kinase negative . Adult pts. with aggress.
systemic mastocytosis (ASM) without the
D816V c-kit mutation .Adjuvant tmt. of
adult pts. follow. complete gross resec. of
Kit (CD117) positive GIST.
C/I: Hypersens.
Tyrosine Kinase Inhibitor. Axitinib 1 mg, 5 mg. F.C. TAB: 28, 56, 60, 180 × 5, 1 mg.
Recomm. init. oral dose is 5 mg×2/d. approx. 12 hrs. apart with/without food. Should be swallow. whole with a glass of water. If the pt. vomits or misses a dose, an addit. dose should not be taken. The next prescribed dose should be taken at the usual time. See lit.
Tmt. of advanc. RCC after fail. of one prior syst. therapy.
C/I: Hypersens.
